Search

Your search keyword '"Berkova, Zuzana"' showing total 315 results

Search Constraints

Start Over You searched for: Author "Berkova, Zuzana" Remove constraint Author: "Berkova, Zuzana"
315 results on '"Berkova, Zuzana"'

Search Results

7. Tumoral microbial and pathway alterations associated with young-onset rectal cancer and its response to therapy.

11. OA-36 SBCMA predicts progression and is a biomarker of response in myeloma precursor disease followed on prospective studies

12. P-399 Isatuximab promotes immune activation in the bone marrow microenvironment of patients with high risk smoldering multiple myeloma

15. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma

16. Abstract 775: Integrative genomic and transcriptomic profiling of myeloma precursors in a prospective longitudinal observational study (ORIGIN)

20. Supplementary Figures from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

21. Supplementary Figure Legends from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

22. Supplementary Tables from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

23. IsletSwipe, a mobile platform for expert opinion exchange on islet graft images

24. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma

32. Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments

33. Gene expression profiling predicts relapse‐free and overall survival in newly diagnosed myeloma patients treated with novel therapies

34. Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

35. SARS-CoV-2 in multiple myeloma: initial observation and management

37. A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

41. The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells

42. Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma

43. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis

44. Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

45. Activating KRAS, NRAS, and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance

46. Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia?

48. Ten-year follow-up of pentostatin combined with cyclophosphamide, and rituximab in previously untreated indolent B-cell lymphoma.

49. Lymphoid hyperplasia and lymphoma in KSHV K1 transgenic mice

50. Combining Donor Characteristics with Immunohistological Data Improves the Prediction of Islet Isolation Success

Catalog

Books, media, physical & digital resources